Pharmacogenomics: "Noninferiority" is sufficient for initial implementation

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 348-350

  Altman, R B ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CETUXIMAB; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRASTUZUMAB; WARFARIN; PRESCRIPTION DRUG;

COST BENEFIT ANALYSIS; ELECTRONIC MEDICAL RECORD; GENE SEQUENCE; GENETIC ASSOCIATION; GENETICS; GENOMICS; GENOTYPE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; NOTE; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG EFFICACY; REVIEW;

COST-BENEFIT ANALYSIS; GENOME; GENOMICS; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK;

EID: 79951803720     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.310     Document Type: Note

References (6)

1. Altman, R.B. PharmGKB: a logical home for knowledge relating genotype to drug response phenotype. Nat. Genet. 39, 426 (2007).
2. Ashley, E.A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
3. James, T.H., Helms, M.L. & Braund, R. Analysis of medications returned to community pharmacies. Ann. Pharmacother. 43, 1631-1635 (2009).
4. Payne, K. & Shabaruddin, F.H. Costeffectiveness analysis in pharmacogenomics. Pharmacogenomics 11, 643-646 (2010).
5. Sperling, H. et al. Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. J. Urol. 169, 1048-1051 (2003).
6. Epstein, R.S. et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55, 2804-2812 (2010).